Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

Ágora es el programa de Aragón Radio dedicado a la investigación y divulgación científica que dirige y presenta Marcos Ruiz. Su nombre no es casual: responde al objetivo de convertirse en un lugar de encuentro para investigadores, docentes, científicos, estudiantes, empresas, espíritus innovadores y proyectos tecnológicos. Cada noche, a partir de las nueve y media, Ágora ofrece la actualidad del mundo de la ciencia. Además, el programa de divulgación científica trata de una forma tan accesible como seria y rigurosa, sin olvidar la parte más divertida que llega de la mano del cine, el humor o la música.

Ágora es el programa de Aragón Radio dedicado a la investigación y divulgación científica que dirige y presenta Marcos Ruiz. Su nombre no es casual: responde al objetivo de convertirse en un lugar de encuentro para investigadores, docentes, científicos, estudiantes, empresas, espíritus innovadores y proyectos tecnológicos. Cada noche, a partir de las nueve y media, Ágora ofrece la actualidad del mundo de la ciencia. Además, el programa de divulgación científica trata de una forma tan accesible como seria y rigurosa, sin olvidar la parte más divertida que llega de la mano del cine, el humor o la música.

Ágora es el programa de Aragón Radio dedicado a la investigación y divulgación científica que dirige y presenta Marcos Ruiz.&nbsp;Su nombre no es casual: responde al objetivo de convertirse en un lugar de encuentro para investigadores, docentes, científicos, estudiantes, empresas, espíritus innovadores y proyectos tecnológicos. Cada noche, a partir de las nueve y media, Ágora ofrece la actualidad del mundo de la ciencia. Además, el programa de divulgación científica&nbsp;trata de una forma tan accesible como seria y rigurosa, sin olvidar la parte más divertida&nbsp;que llega de la mano del cine, el humor o la música.

Ágora

BilimFili Podcast

Farm. Food. Facts. And everything in between. A podcast featuring the leading minds in the future of sustainable food systems. Brought to you by U.S. Farmers &amp; Ranchers in Action.

Farm. Food. Facts. And everything in between. A podcast featuring the leading minds in the future of sustainable food systems. Brought to you by U.S. Farmers & Ranchers in Action.

Farm Food Facts

Helping my daughter assume her rightful place as Minerva’s sacred symbol.

Coroneus Phocis

基智一点是一款讨论心智基本原理的半月更播客。在每一期节目中，两位主播会与来自神经科学、心理学、计算机科学或哲学等领域的嘉宾共同探讨一个与智能相关的主题。我们以原始文献为蓝本，聚正反两面，旁征博引地讨论智能的原理。以围炉夜谈的形式，邀三五好友，深入浅出地解剖关于心智的思考。我们邀请您一起，一点一点地了解智能的基本原则。

基智一点是一款讨论心智基本原理的半月更播客。在每一期节目中，两位主播会与来自神经科学、心理学、计算机科学或哲学等领域的嘉宾共同探讨一个与智能相关的主题。我们以原始文献为蓝本，聚正反两面，旁征博引地讨论智能的原理。以围炉夜谈的形式，邀三五好友，深入浅出地解剖关于心智的思考。我们邀请您一起，一点一点地了解智能的基本原则。

基智一点是一款讨论心智基本原理的半月更播客。在每一期节目中，两位主播会与来自神经科学、心理学、计算机科学或哲学等领域的嘉宾共同探讨一个与智能相关的主题。我们以原始文献为蓝本，聚正反两面，旁征博引地讨论智能的原理。以围炉夜谈的形式，邀三五好友，深入浅出地解剖关于心智的思考。我们邀请您一起，一点一点地了解智能的基本原则。

基智一点

O podcast cinética é um guia conciso para quem tem pressa, porém, é abrangente, de tudo o que precisamos saber, desde os mistérios da teoria da relatividade a biodiversidade do Brasil. Aumente o som, aperte o play e sinta a reação cinética que vem por ai já neste primeiro episódio

Cinética

Dies ist der offizielle Podcast von Sci-Faith. Hier erscheinen in wöchentlichen Abständen Folgen rund um das Thema Glaube und Wissenschaft.

Sci-Faith ist ein Ausdruck für die Überzeugung, dass Glaube und Wissenschaft ohne Probleme vereinbar sind.
Die Vision von Sci-Faith ist es, zu zeigen, dass eine auf den Glauben aufgebaute Wissenschaft mehr Frucht bringen kann als eine den Glauben leugnende. Mehr über Sci-Faith erfährst Du unter https://sci-faith.de.

Dies ist der offizielle Podcast von Sci-Faith. Hier erscheinen in wöchentlichen Abständen Folgen rund um das Thema Glaube und Wissenschaft. Sci-Faith ist ein Ausdruck für die Überzeugung, dass Glaube und Wissenschaft ohne Probleme vereinbar sind. Die Vision von Sci-Faith ist es, zu zeigen, dass eine auf den Glauben aufgebaute Wissenschaft mehr Frucht bringen kann als eine den Glauben leugnende. Mehr über Sci-Faith erfährst Du unter https://sci-faith.de.

Sci-Faith

Literature Podcast from the Cardiovascular Module of the TUM

Literature Podcast

ÄrzteTag extra – ein neuer Podcast der "Ärzte Zeitung". In diesen Episoden sprechen wir mit freundlicher Unterstützung durch Partner etwa aus der Industrie über Neuigkeiten und Innovationen in Medizin und Forschung. Wir thematisieren aktuelle klinische Themen und lassen Experten zu Wort kommen.

ÄrzteTag extra

EasyLife - dein Weg zu mehr Leichtigkeit. Dieser Podcast verbindet Neurowissenschaft, positive Psychologie, Business und Lebensfreude zu einem Potpourri an Möglichkeiten. Dich erwarten Erkenntnisse aus 15 Jahren Forschung, Projekt-Arbeit und Coaching, aus meinen persönlichen Geschichten als Berufsneugierige und Soziobiologin sowie Interviews mit interessanten Menschen sämtlicher Fasson.

EasyLife

Hello World!
We are Holly and Joseph, just two more people like you motivated to contribute to a change in the way of thinking of our current society, from the deepest part of us we come with this idea of carrying out a podcast called “Climate Change With Holly” in which we would like to reach the ears of all you wonderful people who agree to make this world a friendly and beautiful place for all.

Hello World! We are Holly and Joseph, just two more people like you motivated to contribute to a change in the way of thinking of our current society, from the deepest part of us we come with this idea of carrying out a podcast called “Climate Change With Holly” in which we would like to reach the ears of all you wonderful people who agree to make this world a friendly and beautiful place for all.

Climate Change with Holly

Este podcast tiene como objetivo principal educar, formar, actualizar a todas las personas apasionadas por la ciencia. 
Hablaremos de curiosidades científicas, investigaciones recientes, técnicas aplicadas casos clínicos.

Este podcast tiene como objetivo principal educar, formar, actualizar a todas las personas apasionadas por la ciencia. Hablaremos de curiosidades científicas, investigaciones recientes, técnicas aplicadas casos clínicos.

Hablemos de Ciencia y de Investigación

Welcome to PBRI Podcasts, a series that explores some of Australia's most unwanted plant pests. 
It features interviews with growers and agronomists on their first-hand experience in managing new and emerging pests, leading Australian researchers on their latest findings and observations and international experts who share their experiences and learnings. 
Each episode runs for about 30 minutes, and you can listen in any order you want.
The first series of PBRI Podcasts is on fall armyworm. It explores the experiences and observations of experts from around the globe and here in Australia as we prepare to take on this invasive pest.
Throughout the series, host Chris Brown delves into the biology and behaviour of fall armyworm and explores how we can best prepare ourselves in order to minimise its impact.

Welcome to PBRI Podcasts, a series that explores some of Australia's most unwanted plant pests. It features interviews with growers and agronomists on their first-hand experience in managing new and emerging pests, leading Australian researchers on their latest findings and observations and international experts who share their experiences and learnings. Each episode runs for about 30 minutes, and you can listen in any order you want. The first series of PBRI Podcasts is on fall armyworm. It explores the experiences and observations of experts from around the globe and here in Australia as we prepare to take on this invasive pest. Throughout the series, host Chris Brown delves into the biology and behaviour of fall armyworm and explores how we can best prepare ourselves in order to minimise its impact.

Fall armyworm

Welcome to the Rookie Researcher Podcast! My name is Redmond Scales, and I am a PhD candidate in UCDs School of Politics and International Relations. The aim of this podcast is to give postgraduate researchers the chance to discuss their research topics in a casual environment so you, the listener, can learn about their research topics and the challenges that they face.

The Rookie Researcher Podcast

Wonder Why e Fondazione AIRC presentano Science Uncovered: un viaggio attraverso storie appassionanti di persone e scoperte, vecchie e nuove, capaci di raccontare lo straordinario valore della ricerca scientifica, e di dare una risposta a domande che tutti ci poniamo: per esempio, come sarò fra dieci anni? Perché alcune persone si ammalano e altre no? Perché la ricerca da sempre si nutre di due elementi fondamentali: curiosità e meraviglia. E noi siamo pronti a viverli insieme.

Wonder Why e Fondazione AIRC presentano Science Uncovered: un viaggio attraverso storie appassionanti di persone e scoperte, vecchie e nuove, capaci di raccontare lo straordinario valore della ricerca scientifica, e di dare una risposta a domande che tutti ci poniamo: per esempio, come sarò fra dieci anni? Perché alcune persone si ammalano e altre no? Perché la ricerca da sempre si nutre di due elementi fondamentali: curiosità e meraviglia. E noi siamo pronti a viverli insieme.

Wonder Why e Fondazione AIRC presentano Science Uncovered: un viaggio attraverso storie appassionanti di persone e scoperte, vecchie e nuove, capaci di raccontare lo straordinario valore della ricerca scientifica, e di dare una risposta a domande che tutti ci poniamo: per esempio, come sarò fra dieci anni? Perché alcune persone si ammalano e altre no? Perché la ricerca da sempre si nutre di due elementi fondamentali: curiosità e meraviglia. E noi siamo pronti a viverli insieme.

Science Uncovered

"А это еще кто?"

Preguntar, preguntar, preguntar. Mejor una buena pregunta que una mala respuesta. Este es un podcast de filosofía con Guadalupe Reinoso, Licenciada y Doctora en Filosofía por la UNC y profesora regular en la Facultad de Filosofía y Humanidades.

Crónicas Filosóficas

A podcast from the Otway Agroforestry Network. &nbsp; We encourage farmers to plant trees for the reasons that matter to them. &nbsp; Trees on farms are important for livestock welfare and can improve the water quality in our creeks and streams. &nbsp; Agroforestry trees expand and connect wildlife habitats, capture and store carbon dioxide, reduce the need to harvest our public native forests and provide regional business and employment opportunities. OAN (Otway Agroforestry Network Ltd) is a grassroots Australian landcare group.&nbsp;

A podcast from the Otway Agroforestry Network.   We encourage farmers to plant trees for the reasons that matter to them.   Trees on farms are important for livestock welfare and can improve the water quality in our creeks and streams.   Agroforestry trees expand and connect wildlife habitats, capture and store carbon dioxide, reduce the need to harvest our public native forests and provide regional business and employment opportunities. OAN (Otway Agroforestry Network Ltd) is a grassroots Australian landcare group. 

For The Love Of Trees

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

《认知心理学》（第8版）是关于认知心理学的基础知识和研究成果，由美国心理学家索尔所教授所著。该书涵盖了感觉、知觉、注意、记忆、意识、知识表征、概念形成、推理、决策、问题解决、创造、人类智力、语言以及人工智能等。书中不仅介绍了大量经典的认知心理学实验，而且对认知神经科学的研究成果给与了高度重视和充分表述。

认知心理学：开启认识世界的全新大门

＜概要＞
数学は、自然の法則を表現するための美しい言語です。
このポッドキャストでは、数学の基礎から応用まで様々なテーマを取り扱い、数学の魅力をお伝えします。数学が好きな人も、苦手意識を持っている人も、ぜひ数学の魅力に触れてみてください。

＜初めての方へ＞
数学沼ラジオのトピックレベルを知りたい場合　→　#1
みんな知ってる数学をさらに深堀りしたい場合　→　#6
日常生活の中でもっと数学を感じたい場合　　　→　#8

＜概要＞ 数学は、自然の法則を表現するための美しい言語です。 このポッドキャストでは、数学の基礎から応用まで様々なテーマを取り扱い、数学の魅力をお伝えします。数学が好きな人も、苦手意識を持っている人も、ぜひ数学の魅力に触れてみてください。 ＜初めての方へ＞ 数学沼ラジオのトピックレベルを知りたい場合 → #1 みんな知ってる数学をさらに深堀りしたい場合 → #6 日常生活の中でもっと数学を感じたい場合 → #8

数学沼ラジオ

Farming Focus

This is your Bird Flu Intel: Facts, Not Fear, on H5N1 podcast. Bird Flu Intel: Facts, Not Fear on H5N1 is your go-to podcast for reliable and evidence-based information on the avian influenza virus. In a world where misinformation spreads rapidly, it’s vital to separate fact from fiction, and this podcast is dedicated to doing just that. Hosted by experts and structured to debunk myths surrounding H5N1, each episode features a concise, rational examination of common misconceptions about the virus. Through engaging dialogues between our [FACT CHECKER] and [SCIENTIST], you’ll gain clarity on myths such as the exaggerated spread of H5N1 to humans or misunderstanding its actual impact. Hear scientific evidence that dispels these myths, making the complex simple and accessible. Learn about the mechanisms of misinformation, how it can multiply fear, and the harm it causes. Equip yourself with powerful tools to evaluate the quality of information, ensuring you can discern credible sources from unreliable ones. Stay informed with the current scientific consensus on key aspects of H5N1 and explore areas where questions remain unanswered, providing a balanced view of what’s known and what’s still emerging. Regularly updated, Bird Flu Intel empowers you with the knowledge you need to stay informed, stay safe, and keep fear at bay. Tune in to replace anxiety with understanding, and transform uncertainty into informed awareness. For more info go to <a href="https://www.quietplease.ai" target="_blank" rel="noreferrer noopener">https://www.quietplease.ai</a> Or these great deals  and more <a href="https://amzn.to/4hSgB4r" target="_blank" rel="noreferrer noopener">https://amzn.to/4hSgB4r</a> This show includes AI-generated content.

This is your Bird Flu Intel: Facts, Not Fear, on H5N1 podcast.Bird Flu Intel: Facts, Not Fear on H5N1 is your go-to podcast for reliable and evidence-based information on the avian influenza virus. In a world where misinformation spreads rapidly, it’s vital to separate fact from fiction, and this podcast is dedicated to doing just that. Hosted by experts and structured to debunk myths surrounding H5N1, each episode features a concise, rational examination of common misconceptions about the virus.Through engaging dialogues between our [FACT CHECKER] and [SCIENTIST], you’ll gain clarity on myths such as the exaggerated spread of H5N1 to humans or misunderstanding its actual impact. Hear scientific evidence that dispels these myths, making the complex simple and accessible. Learn about the mechanisms of misinformation, how it can multiply fear, and the harm it causes. Equip yourself with powerful tools to evaluate the quality of information, ensuring you can discern credible sources from unreliable ones.Stay informed with the current scientific consensus on key aspects of H5N1 and explore areas where questions remain unanswered, providing a balanced view of what’s known and what’s still emerging. Regularly updated, Bird Flu Intel empowers you with the knowledge you need to stay informed, stay safe, and keep fear at bay. Tune in to replace anxiety with understanding, and transform uncertainty into informed awareness.For more info go to https://www.quietplease.aiOr these great deals and more https://amzn.to/4hSgB4rThis show includes AI-generated content.

This is your Bird Flu Intel: Facts, Not Fear, on H5N1 podcast. Bird Flu Intel: Facts, Not Fear on H5N1 is your go-to podcast for reliable and evidence-based information on the avian influenza virus. In a world where misinformation spreads rapidly, it’s vital to separate fact from fiction, and this podcast is dedicated to doing just that. Hosted by experts and structured to debunk myths surrounding H5N1, each episode features a concise, rational examination of common misconceptions about the virus. Through engaging dialogues between our [FACT CHECKER] and [SCIENTIST], you’ll gain clarity on myths such as the exaggerated spread of H5N1 to humans or misunderstanding its actual impact. Hear scientific evidence that dispels these myths, making the complex simple and accessible. Learn about the mechanisms of misinformation, how it can multiply fear, and the harm it causes. Equip yourself with powerful tools to evaluate the quality of information, ensuring you can discern credible sources from unreliable ones. Stay informed with the current scientific consensus on key aspects of H5N1 and explore areas where questions remain unanswered, providing a balanced view of what’s known and what’s still emerging. Regularly updated, Bird Flu Intel empowers you with the knowledge you need to stay informed, stay safe, and keep fear at bay. Tune in to replace anxiety with understanding, and transform uncertainty into informed awareness. For more info go to <a href="https://www.quietplease.ai" rel="noopener noreferrer">https://www.quietplease.ai</a> Or these great deals&nbsp; and more <a href="https://amzn.to/4hSgB4r" rel="noopener noreferrer">https://amzn.to/4hSgB4r</a> This show includes AI-generated content.

Bird Flu Intel: Facts, Not Fear, on H5N1

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit This show includes AI-generated content.

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside witThis show includes AI-generated content.

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit This show includes AI-generated content.

Malaria Vaccine

Bienvenidos a Campo 360, el espacio donde conectamos el conocimiento con la ciencia y exploramos los temas más relevantes y desafiantes del mundo agropecuario. Donde desentrañamos los misterios de la tierra y el campo, sin filtros y con toda la verdad.

Bienvenidos a Campo 360, el espacio donde conectamos el conocimiento con la ciencia y exploramos los temas más relevantes y desafiantes del mundo agropecuario. Donde desentrañamos los misterios de la tierra y el campo, sin filtros y con toda la verdad.

Campo360

'Thrive in Construction' is the only podcast that delves into the personal journeys of sustainability leaders and innovators in the construction industry across the UK. Our show differentiates by offering unscripted, passion-fueled conversations that go beyond the buzzwords to the heart of what's driving the industry forward. It's tailored for aspiring professionals, seasoned experts, and anyone with a keen interest in the sustainable evolution of construction. We're here at a time when the call for sustainable development is not just a trend, but a societal imperative, empowering listeners to build a career that contributes to a greener future.

'Thrive in Construction' is the only podcast that delves into the personal journeys of sustainability leaders and innovators in the construction industry across the UK. Our show differentiates by offering unscripted, passion-fueled conversations that go beyond the buzzwords to the heart of what's driving the industry forward. It's tailored for aspiring professionals, seasoned experts, and anyone with a keen interest in the sustainable evolution of construction. We're here at a time when the call for sustainable development is not just a trend, but a societal imperative, empowering listeners to build a career that contributes to a greener future.

Thrive In Construction with Darren Evans

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Lung Cancer Update

Hi, I'm Vincent.&nbsp; I'm here to share the latest scientific knowledge on longevity, mind-body, and performance. I hope it'll be helpful~ 嗨，我是黃康銘。 這邊會分享有關老化長壽、身心健康、高效表現的科學新知，希望對大家有幫助～ FB:&nbsp;<a href="https://www.youtube.com/redirect?event=channel_description&amp;redir_token=QUFFLUhqbDhNRUM5YVVwYzFrcG5aeUtQVWFIekJGalZiZ3xBQ3Jtc0ttUU1MRGZLS01EdlFISExhdnhGUllDel9CMnIxYUcwWU04NGJGek5vdkEwdVM3TDZ5djhzdzhBRUJuOVlYUEpEamNTNzJaWW9YajhyNXFYb0JIbzN1UjY2bm1FNThiVDM3bDVXUldKVlNrY08wdndBSQ&amp;q=https%3A%2F%2Fwww.facebook.com%2Fdrvincenthuang">facebook.com/drvincenthuang</a>IG:&nbsp;<a href="https://www.youtube.com/redirect?event=channel_description&amp;redir_token=QUFFLUhqa0l5RV9QV3E0Q190VkdEWV8yR0pDdldFanRLZ3xBQ3Jtc0tsUWRXM0hXNlpEbXdOVXdVQkNBUzExaldhdDVraDV0VWJSUDVDZ3JZdzFSdmFEM1RjbDhxRERXSU9wM0ZzVGZqVW5oYmJlN19PejZJVlRNYjdRdndNNFVkaU0yOFZTRzJLOGZ6R1duQWJxeFNSM2xpdw&amp;q=https%3A%2F%2Fwww.instagram.com%2Fdrvincenthuang%2F">instagram.com/drvincenthuang</a>

Hi, I'm Vincent.  I'm here to share the latest scientific knowledge on longevity, mind-body, and performance. I hope it'll be helpful~ 嗨，我是黃康銘。 這邊會分享有關老化長壽、身心健康、高效表現的科學新知，希望對大家有幫助～ FB: facebook.com/drvincenthuang IG: instagram.com/drvincenthuang

Hi, I'm Vincent.&nbsp; I'm here to share the latest scientific knowledge on longevity, mind-body, and performance. I hope it'll be helpful~ 嗨，我是黃康銘。 這邊會分享有關老化長壽、身心健康、高效表現的科學新知，希望對大家有幫助～ FB:&nbsp;<a href="https://www.youtube.com/redirect?event=channel_description&amp;redir_token=QUFFLUhqbDhNRUM5YVVwYzFrcG5aeUtQVWFIekJGalZiZ3xBQ3Jtc0ttUU1MRGZLS01EdlFISExhdnhGUllDel9CMnIxYUcwWU04NGJGek5vdkEwdVM3TDZ5djhzdzhBRUJuOVlYUEpEamNTNzJaWW9YajhyNXFYb0JIbzN1UjY2bm1FNThiVDM3bDVXUldKVlNrY08wdndBSQ&amp;q=https%3A%2F%2Fwww.facebook.com%2Fdrvincenthuang" rel="noopener noreferrer">facebook.com/drvincenthuang</a>IG:&nbsp;<a href="https://www.youtube.com/redirect?event=channel_description&amp;redir_token=QUFFLUhqa0l5RV9QV3E0Q190VkdEWV8yR0pDdldFanRLZ3xBQ3Jtc0tsUWRXM0hXNlpEbXdOVXdVQkNBUzExaldhdDVraDV0VWJSUDVDZ3JZdzFSdmFEM1RjbDhxRERXSU9wM0ZzVGZqVW5oYmJlN19PejZJVlRNYjdRdndNNFVkaU0yOFZTRzJLOGZ6R1duQWJxeFNSM2xpdw&amp;q=https%3A%2F%2Fwww.instagram.com%2Fdrvincenthuang%2F" rel="noopener noreferrer">instagram.com/drvincenthuang</a>

In control of your biology

Der INLEAD-Podcast "Leading for Inclusion" hat sich als Ziel gesetzt, die Bedeutung von Inklusion zu verdeutlichen und Inklusion in den Fokus zu rücken. Während die Förderung von Vielfalt ein wichtiges Thema bleibt, sollten sowohl private als auch öffentliche Organisationen mehr in die Entwicklung inklusiver Führungs- und Arbeitspraktiken investieren, um gerechte Arbeitsumgebungen für alle zu schaffen.

Wir freuen uns auf spannende Gäste und Diskussionen zum Thema Inklusion sowie auf Feedback und Anregungen aus dem Publikum.

Der INLEAD-Podcast "Leading for Inclusion" hat sich als Ziel gesetzt, die Bedeutung von Inklusion zu verdeutlichen und Inklusion in den Fokus zu rücken. Während die Förderung von Vielfalt ein wichtiges Thema bleibt, sollten sowohl private als auch öffentliche Organisationen mehr in die Entwicklung inklusiver Führungs- und Arbeitspraktiken investieren, um gerechte Arbeitsumgebungen für alle zu schaffen. Wir freuen uns auf spannende Gäste und Diskussionen zum Thema Inklusion sowie auf Feedback und Anregungen aus dem Publikum.

Leading for Inclusion - der Inklusions-Podcast von INLEAD

Klimawandel, Fachkräftemangel, Transformation – alles muss gleichzeitig passieren. Doch wie schaffen wir echten Fortschritt?

Rona van der Zander und Lucas Beyer sprechen in „Jetzt machen!“ mit Menschen, die Wandel möglich machen: Experten, Visionäre und Macher aus Energie, Wirtschaft, Wissenschaft und Politik.

Gemeinsam zeigen sie, wo Transformation heute schon gelingt – und wie wir sie aktiv gestalten können: in Unternehmen, in der Gesellschaft und in uns selbst.

Neue Folgen gibt’s jeden letzten Dienstag im Monat.

Mehr auf unseren Social-Media-Kanälen und unter eon.com/de

Produziert von Podstars by OMR

Klimawandel, Fachkräftemangel, Transformation – alles muss gleichzeitig passieren. Doch wie schaffen wir echten Fortschritt? Rona van der Zander und Lucas Beyer sprechen in „Jetzt machen!“ mit Menschen, die Wandel möglich machen: Experten, Visionäre und Macher aus Energie, Wirtschaft, Wissenschaft und Politik. Gemeinsam zeigen sie, wo Transformation heute schon gelingt – und wie wir sie aktiv gestalten können: in Unternehmen, in der Gesellschaft und in uns selbst. Neue Folgen gibt’s jeden letzten Dienstag im Monat. Mehr auf unseren Social-Media-Kanälen und unter eon.com/de Produziert von Podstars by OMR

Jetzt machen! – Der Energiewende Podcast von E.ON

Welke impact hebben bestrijdingsmiddelen op ons en ons milieu? Waarom gebruiken we ze? Broodnodig of zijn we eraan verslaafd geraakt? Schaden ze onze gezondheid? En zijn er alternatieven? Wetenschapsjournalist Dirk de Bekker neemt je mee op een zoektocht naar antwoorden, 60 jaar na Silent Spring. Rachel Carson zet in Silent Spring de schadelijke effecten van bestrijdingsmiddelen voor het eerst op de kaart bij een groot publiek. Ze moest daarvoor een hoge prijs betalen. Waar staan we 60 jaar later? Is de lente nog te redden?

Red de Lente

“Horsetail” is a podcast about the gardens, parks and preserves around the Bay Area, and the people that care and cultivate these spaces. How can we properly appreciate nature surrounded by highways and skyscrapers? How can we preserve these spaces to the best of our ability? And can we coexist nature with the urban presence of the Bay Area? “Horsetail” aims to explore these questions over an exploration of the sprawl of the city.

“Horsetail” is a podcast about the gardens, parks and preserves around the Bay Area, and the people that care and cultivate these spaces. How can we properly appreciate nature surrounded by highways and skyscrapers? How can we preserve these spaces to the best of our ability? And can we coexist nature with the urban presence of the Bay Area? “Horsetail” aims to explore these questions over an exploration of the sprawl of the city.

Horsetail: Urban Nature in the Bay Area

Sny świadome - okiem praktyka, umyslu scislego, ateisty i sceptyka.

Sny świadome - okiem praktyka, umyslu scislego, ateisty i sceptyka.

Sny świadome okiem sceptyka

Astrophysics, human spaceflight, and other musings 🚀 <a href="https://abhinavspace.substack.com?utm_medium=podcast">abhinavspace.substack.com</a>

Astrophysics, human spaceflight, and other musings 🚀 abhinavspace.substack.com

Astrophysics, human spaceflight, and other musings 🚀 <a href="https://abhinavspace.substack.com?utm_medium=podcast" rel="noopener noreferrer">abhinavspace.substack.com</a>

Science Podcasts / Page 888

Ágora

BilimFili Podcast

Farm Food Facts

Coroneus Phocis

基智一点

Cinética

Sci-Faith

Literature Podcast

ÄrzteTag extra

EasyLife

Climate Change with Holly

Hablemos de Ciencia y de Investigación

Fall armyworm

The Rookie Researcher Podcast

Science Uncovered

"А это еще кто?"

Crónicas Filosóficas

For The Love Of Trees

认知心理学：开启认识世界的全新大门

数学沼ラジオ

Farming Focus

Bird Flu Intel: Facts, Not Fear, on H5N1

Malaria Vaccine

Campo360

Thrive In Construction with Darren Evans

Lung Cancer Update

In control of your biology

Leading for Inclusion - der Inklusions-Podcast von INLEAD

Jetzt machen! – Der Energiewende Podcast von E.ON

Red de Lente

Horsetail: Urban Nature in the Bay Area

Sny świadome okiem sceptyka

Traveling Through Space

ป้าหมอขอเล่า

Rashon's Ability

Wellness Matters for Direct Support

Kratom Science Podcast

Clearheaded

Zia - Audible Women in Science

ОЛЯ КОЛЕВАТОВА О МЫШЛЕНИИ

San Cristóbal tiene memoria

SPG Podcast Show

RespondENDO

CISM 89.3 : L'onde féministe

Let's Talk about CBT- Members Matters

O Psicanalista Palhaço

Lubrication Across The Nation

The 4Farmers Podcast

Faithful Pursuit

Nurturing a Child’s Consciousness: Grow Together in Conscientious Relationships